These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23059775)

  • 1. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
    Jones DR; Moskaluk CA; Gillenwater HH; Petroni GR; Burks SG; Philips J; Rehm PK; Olazagasti J; Kozower BD; Bao Y
    J Thorac Oncol; 2012 Nov; 7(11):1683-90. PubMed ID: 23059775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
    Davies AM; Chansky K; Lara PN; Gumerlock PH; Crowley J; Albain KS; Vogel SJ; Gandara DR;
    J Thorac Oncol; 2009 Jan; 4(1):87-92. PubMed ID: 19096312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
    Taylor MD; Liu Y; Nagji AS; Theodosakis N; Jones DR
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1224-32, 1232.e1. PubMed ID: 20412959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial.
    Pisters KM; Vallières E; Crowley JJ; Franklin WA; Bunn PA; Ginsberg RJ; Putnam JB; Chansky K; Gandara D
    J Clin Oncol; 2010 Apr; 28(11):1843-9. PubMed ID: 20231678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
    Hoang T; Campbell TC; Zhang C; Kim K; Kolesar JM; Oettel KR; Blank JH; Robinson EG; Ahuja HG; Kirschling RJ; Johnson PH; Huie MS; Wims ME; Larson MM; Hernan HR; Traynor AM
    Invest New Drugs; 2014 Feb; 32(1):195-9. PubMed ID: 23728919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
    Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
    Friday BB; Anderson SK; Buckner J; Yu C; Giannini C; Geoffroy F; Schwerkoske J; Mazurczak M; Gross H; Pajon E; Jaeckle K; Galanis E
    Neuro Oncol; 2012 Feb; 14(2):215-21. PubMed ID: 22090453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
    Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).
    Rades D; Setter C; Dunst J; Dahl O; Schild SE; Noack F
    Strahlenther Onkol; 2010 Jun; 186(6):307-14. PubMed ID: 20437013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
    Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
    J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
    Yamane Y; Ishii G; Goto K; Kojima M; Nakao M; Shimada Y; Nishiwaki Y; Nagai K; Kohrogi H; Ochiai A
    J Thorac Oncol; 2010 Jan; 5(1):49-55. PubMed ID: 20035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer.
    Takatani H; Nakamura Y; Nagashima S; Soda H; Kinoshita A; Fukuda M; Fukuda M; Soejima Y; Kasai T; Nakatomi K; Iida T; Oka M; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2012 Sep; 13(5):347-51. PubMed ID: 22264660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
    Socinski MA; Scappaticci FA; Samant M; Kolb MM; Kozloff MF
    J Thorac Oncol; 2010 Mar; 5(3):354-60. PubMed ID: 20032789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.